Real-World Psoriasis Treatment Insights From Winter Clinical Hawaii 2026

Real-world evidence complements clinical trial data by capturing how psoriasis therapies perform across diverse patient populations and treatment contexts in everyday practice.

Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, reducing reliance on corticosteroids and minimizing the need for systemic escalation.

Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient counseling, and versatility in managing psoriatic comorbidities.

Benjamin Lockshin, MD, FAAD, examines how geographic variation in psoriasis patient characteristics and biologic prescribing reflects a complex interplay of insurance access, formulary structure, practice site demographics, and regional socioeconomic factors.

Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.

Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.